Oncologic outcome of metachronous oligometastatic recurrence in advanced cervical cancer patients after primary radio-chemotherapy
10.3802/jgo.2025.36.e99
- Author:
Thomas BARTL
;
Tim DORITTKE
;
Cristina CIOCSIRESCU
;
Johannes KNOTH
;
Maximilian SCHMID
;
Christoph GRIMM
;
Alina STURDZA
- Publication Type:Original Article
- From:Journal of Gynecologic Oncology
2025;36(6):e99-
- CountryRepublic of Korea
- Language:English
-
Abstract:
Objective:Systemic chemotherapy in recurrent cervical cancer is a palliative treatment approach with limited oncologic outcome. As emerging evidence supports favorable prognosis following radical local treatment strategies for oligometastatic recurrence in gynecologic malignancies, there is an unmet clinical need to define prognostic implications of surgical metastasectomy in recurrent cervical cancer.
Methods:Data of 139 consecutive cervical cancer patients, who underwent primary external-beam radiotherapy with concomitant chemotherapy, followed by magnetic resonance image-guided adaptive brachytherapy between 2015 and 2019, was analyzed.Oncologic outcomes of recurrence patterns, defined according to the European Society for Radiotherapy and Oncology (ESTRO) and the American Society for Radiation Oncology (ASTRO) consensus, was assessed according to the type of recurrence therapy.
Results:Of 54 patients (38.8%) with metachronous disease recurrence, 21 (38.8%) classified as metastatic and 22 (40.7%) as oligometastatic. Oligometastatic recurrence was associated with improved progression-free survival after recurrence (PFS2; hazard ratio [HR]=2.95;95% confidence interval [CI]=1.23–7.08; p=0.015) and disease-specific survival after recurrence (HR=3.28; 95% CI=1.40–7.70; p=0.006) irrespective of the type of recurrence therapy. An exploratory subgroup analysis of oligometastatic patients undergoing surgical resection ± adjuvant therapy (n=12) suggested reduced risk of second disease recurrence (odds ratio=0.15; 95% CI=0.02–0.92; p=0.020) and improved PFS2 (HR=0.24; 95% CI=0.06–0.99; p=0.048) as compared to palliative systemic treatment (n=7).
Conclusion:A relevant number of recurrences qualifies as oligometastatic according to the ESTRO-ASTRO consensus, which associate with improved prognosis irrespective of the type of recurrence therapy. Patients experiencing oligometastatic recurrence should be carefully evaluated for potentially curative treatment approaches.
